WO2021187745A1 - 중간엽 줄기세포 또는 중간엽 줄기세포에서 분비된 인슐린을 포함하는 샤르코-마리-투스병 예방 또는 치료용 약학적 조성물 - Google Patents
중간엽 줄기세포 또는 중간엽 줄기세포에서 분비된 인슐린을 포함하는 샤르코-마리-투스병 예방 또는 치료용 약학적 조성물 Download PDFInfo
- Publication number
- WO2021187745A1 WO2021187745A1 PCT/KR2021/000941 KR2021000941W WO2021187745A1 WO 2021187745 A1 WO2021187745 A1 WO 2021187745A1 KR 2021000941 W KR2021000941 W KR 2021000941W WO 2021187745 A1 WO2021187745 A1 WO 2021187745A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- insulin
- stem cells
- mesenchymal stem
- marie
- charcot
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
Definitions
- the present invention was made by the project specific number HI14C3484 under the support of the Ministry of Health and Welfare. Research on basic technology and next-generation technology", organized by Samsung Seoul Hospital, and the research period is from January 1, 2020 to December 31, 2020.
- the present invention was made by the project specific number GFO3190121 under the support of the Samsung Seoul Hospital internal project. Development of customized diagnosis and treatment for Marie-Tooth disease", organized by Samsung Seoul Hospital, and the research period is from January 1, 2014 to December 31, 2020.
- the present invention was made by the project specific number S2644635 under the support of the Small and Medium Business Technology Information Promotion Agency. "Development of next-generation rare muscle disease treatment using Enhanced Neo Cell", the lead institution is Encell Co., Ltd., and the research period is from 2018.08.01 to 2020.07.31.
- the present invention relates to a pharmaceutical composition for preventing or treating Charcot-Marie-Tooth disease, comprising mesenchymal stem cells or insulin secreted from mesenchymal stem cells.
- Mesenchymal stem cells are cells of stromal origin, have the characteristics of self-renewal, and can be differentiated into bone, cartilage, adipose tissue, muscle, tendon, ligament, and nervous tissue. It is attracting attention as a cell suitable for therapy.
- mesenchymal stem cells present in the bone marrow have a limited scope of application due to their limited differentiation and proliferative ability. It is usually accompanied by time, mental and physical pain.
- mesenchymal stem cells present in the bone marrow have a limited scope of application due to their limited differentiation and proliferative ability. It is usually accompanied by time, mental and physical pain.
- bone marrow transplantation there is a problem in that it is necessary to find a donor that does not show a graft-versus-host reaction because the antigen phenotype is matched through histocompatibility antigen comparison.
- the umbilical cord can be obtained through a simple procedure during childbirth, and contains numerous hematopoietic stem cells and stem cells compared to its quantity. Recently, as it is known that there are a large amount of stem cells in the umbilical cord, placenta, umbilical cord blood, etc., research is being actively conducted. However, it has not yet been reported that mesenchymal stem cells isolated and cultured from the umbilical cord or factors secreted from mesenchymal stem cells inhibit muscle cell death.
- IPN Inherited peripheral neuropathy
- CMT Charcot-Marie-Tooth disease
- HMSN hereditary motor and sensory neuropathy
- HNPP hereditary neuropathy with liability to pressure palsy
- HN hereditary motor neuropathy
- HSAN hereditary sensory and autonomic neuropathy
- Charcot-Marie-Tooth disease is an inherited neuromuscular disease associated with various gene mutations that cause axonal degeneration of peripheral nerves.
- the main clinical features are muscle loss and loss of sensation in the distal center of the upper and lower extremities. It has been reported that the clinical course of the disease may vary not only between different subtypes but also within the same subtype, so close monitoring of patients is required.
- Charcot-Marie-Tooth disease is the most common disease among IPN with a frequency of 1 in 2,500, and has clinical features such as muscle atrophy, weakness, foot deformity, and loss of sensation in the legs as the disease progresses. Symmetrical distal polyneuropathy.
- therapeutics for genetic recessive diseases include gene therapy, enzyme replacement therapy, and cell transplantation, but these clinical approaches are the most common treatment methods for dominant diseases caused by gain-of-function of mutant proteins. cases are limited.
- Various treatments have been proposed to prevent the harmful effects of these mutant proteins, but the basic treatment should be based on suppression or elimination of the expression of the mutant allele or protein.
- the present inventors confirmed that insulin secreted from mesenchymal stem cells or mesenchymal stem cells has the effect of promoting the proliferation ability of Schwann cells, and completed the treatment for Charcot-Marie-Tooth disease with a mechanism of restoring myelination through this. .
- an object of the present invention is to provide a pharmaceutical composition for preventing or treating Charcot-Marie-Tooth disease, comprising mesenchymal stem cells or insulin secreted from mesenchymal stem cells.
- Another object of the present invention is to provide a pharmaceutical composition for preventing or treating Charcot-Marie-Tooth disease comprising insulin or a derivative thereof as an active ingredient.
- Another object of the present invention is to provide a stem cell therapeutic agent for treating Charcot-Marie-Tooth disease, comprising mesenchymal stem cells or insulin secreted from mesenchymal stem cells.
- the present invention relates to a pharmaceutical composition for preventing or treating Charcot-Marie-Tooth disease, comprising mesenchymal stem cells or insulin secreted from mesenchymal stem cells.
- One example of the present invention relates to a pharmaceutical composition for preventing or treating Charcot-Marie-Tooth disease, including mesenchymal stem cells.
- meenchymal stem cells refers to pluripotent progenitor cells before differentiation into cells of specific organs, such as bone, cartilage, fat, tendon, nerve tissue, fibroblasts, and muscle cells.
- the mesenchymal stem cells may have insulin-secreting ability.
- the mesenchymal stem cells may include insulin.
- insulin may be secreted from mesenchymal stem cells, but is not limited thereto.
- the mesenchymal stem cells may be contained in the composition in an undifferentiated state.
- the mesenchymal stem cells may be derived from humans or mammals other than humans, for example, may be derived from a human fetus.
- mammals other than humans may be dogs, cats, monkeys, cattle, sheep, pigs, horses, rats, mice or guinea pigs, but is not limited thereto.
- the mesenchymal stem cells are tonsils, umbilical cord, backpack, placenta, umbilical cord, umbilical cord blood, skin, peripheral blood, bone marrow, adipose tissue, muscle, liver, nerve tissue, periosteum, fetal membrane, synovial membrane, synovial fluid, amniotic membrane, meniscus It may be derived from the superior cartilage, anterior cruciate ligament, articular chondrocytes, baby teeth, perivascular cells, trabecular bone, subpatellar fat mass, spleen and thymus, etc., and may be derived from, for example, human tonsils or human umbilical cord. .
- the method for isolating mesenchymal stem cells in the present invention is known in the art, for example, human tonsils, umbilical cord, backpack, placenta, umbilical cord, umbilical cord blood, skin, peripheral blood, bone marrow, adipose tissue, muscle, liver , nerve tissue, periosteum, fetal membrane, synovial membrane, synovial fluid, amniotic membrane, meniscus, anterior cruciate ligament, articular chondrocytes, dendritic cells, perivascular cells, arachnoid bone, subpatellar fat mass, spleen and thymus, etc.
- the present invention is not limited thereto.
- the isolated mesenchymal stem cells may be cultured if necessary.
- the mesenchymal stem cells can be injected into a patient's body either alone or in a cultured state in an incubator, for example, Lindhoff et al. (1989, Arch. Neurol. 46: 615-31) or Douglas Conn.
- an incubator for example, Lindhoff et al. (1989, Arch. Neurol. 46: 615-31) or Douglas Conn.
- the clinical method published by Chiolka Douglas Kondziolka, Pittsburgh, 1998) may be used, but is not limited thereto.
- the mesenchymal stem cells defined by the International Society for Cellular Therapy (ISCT) should grow attached to the bottom in culture conditions, be able to differentiate into osteoblasts, adipocytes or chondrocytes in vitro, and be capable of differentiating into osteoblasts, adipocytes or chondrocytes, and the cell surface.
- ISCT International Society for Cellular Therapy
- markers CD73, CD90, CD105, CD166 and CD44 should be expressed (positive markers), and CD34, CD45, CD19, CD11b, CD14 and HLA-DR should not be expressed (negative markers).
- the formulation may include a conventional pharmaceutically acceptable carrier in addition to the mesenchymal stem cells, and in the case of an injection, a preservative, an analgesic agent, a solubilizer or stabilizer, and in the case of a topical formulation, a base, excipient, lubricant or preservatives and the like.
- the pharmaceutical composition may further include a pharmaceutically acceptable carrier, and the carrier is commonly used in formulations, including lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, Calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and minerals It may include oil and the like, but is not limited thereto.
- the carrier is commonly used in formulations, including lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, Calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and
- the pharmaceutical composition may further include a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like in addition to the above components, but is not limited thereto.
- the pharmaceutical composition of the present invention is prepared in unit dosage form by formulating using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by a person of ordinary skill in the art to which the present invention pertains. or may be prepared by incorporation into a multi-dose container.
- the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, and may additionally contain a dispersing agent or a stabilizing agent.
- the pharmaceutical composition of the present invention can be administered parenterally, and can be administered intravenously, subcutaneously, intraperitoneally or locally, and preferably can be administered directly to the site of the lesion.
- composition for parenteral administration eg, injection
- a pharmaceutically acceptable carrier for example, sterile purified water, a buffer of about pH 7, or physiological saline. It can be injected into a living body and, if necessary, may include conventional additives such as preservatives and stabilizers, but is not limited thereto.
- the dosage form of the pharmaceutical composition according to the present invention may vary depending on the method of use, but warning agents (Plasters), granules (Granule), powders (Powders), syrups (Syrups), solutions (solutions), fluid extracts (FluidextractsI) , emulsions, suspensions, infusions, tablets, injections, capsules and pills, etc., but are not limited thereto.
- Suitable formulations of the pharmaceutical compositions according to the invention depend on the route of administration chosen. Any of the known techniques, carriers and excipients may be used suitably and as understood in the art, for example, Remingston's Pharmaceutical Sciences described above.
- the amount of mesenchymal stem cells injected in the present invention may be administered at 10 3 to 10 10 cells/time, preferably 10 3 to 10 9 cells/time, most preferably 5 x 10 4 cells/time. It may be administered in a circuit, but is not limited thereto.
- Insulin injected in the present invention may be administered from 0.0001 ng to 500 mg/time, and preferably from 0.0001 mg to 200 mg/time, but is not limited thereto.
- the dosage of the pharmaceutical composition in the present invention is variously prescribed according to factors such as formulation method, administration method, age, weight, sex, pathology, food, administration time, administration route, excretion rate, and response sensitivity of the patient. can be
- prevention refers to any action that inhibits or delays the progression of Charcot-Marie-Tooth disease by administration of the pharmaceutical composition of the present invention.
- treatment refers to any action in which Charcot-Marie-Tooth disease is improved or changed to a beneficial effect by administration of the composition of the present invention.
- Another embodiment of the present invention relates to a pharmaceutical composition for preventing or treating Charcot-Marie-Tooth disease comprising insulin or a derivative thereof as an active ingredient.
- Insulin in the present invention may be naturally produced and derived from mesenchymal stem cells, but is not limited thereto.
- the insulin when naturally produced insulin, it includes, but is not limited to, insulin having a wild-type amino acid sequence of insulin usually associated with animals.
- Naturally produced insulin in the present invention includes, but is not limited to, variants of naturally produced insulin.
- Insulin in the present invention may include, without limitation, proteins, analogs, derivatives, and mutants thereof recombined by a method known in the art as long as they have biological activity to achieve the effect of preventing or treating Charcot-Marie-Tooth disease.
- the mutation may be a mutation found in nature or an artificial mutation that has or does not have the effect of substituting, deleting or inserting one or more amino acids into a nucleic acid sequence encoding insulin.
- the mutation may have a conservative amino acid substitution that does not affect insulin expression, and is 80%, 85%, 90%, 95%, 96%, 97%, 98%, amino acid sequences with 99% or 100% identity.
- insulin includes fragments, deletions, truncated polypeptides, etc., and may be fragments in which amino acid residues are removed from natural insulin. Such fragments, deletions, truncations, etc. do not substantially adversely affect the activity of the resulting polypeptide.
- the activation domain of insulin can be derived by mapping the protein domain of insulin or through truncation from the C-terminus, N-terminus, or both C- and N-terminal ends, such truncated polypeptides may have virtually no negative effect on activity or may indicate an increase in activity.
- recombinant when used in reference to a cell, typically indicates that the cell has been modified by the introduction of a foreign nucleic acid sequence or that the cell is derived from a cell so modified.
- a recombinant cell may contain a gene that is not found in the same form in the native (non-recombinant) form of the cell, or the recombinant cell contains a native gene (found in the native form of the cell). However, these genes have been modified and reintroduced into the cell.
- Recombinant cells may contain nucleic acids endogenous to the modified cell without removal of the nucleic acid from the cell, and such modifications include those obtained by gene substitution, site-specific mutagenesis, and related techniques known to those skilled in the art.
- Recombinant DNA technology includes techniques for producing recombinant DNA in vitro and delivering such recombinant DNA into cells where it can be expressed or propagated to produce a recombinant polypeptide.
- “Recombinant”, “recombining”, and “recombined” of a polynucleotide or nucleic acid generally refer to assembling or combining two or more nucleic acid or polynucleotide strands or fragments to produce a new polynucleotide or nucleic acid.
- Recombinant polynucleotides or nucleic acids are sometimes referred to as chimeras.
- a nucleic acid or polypeptide, when artificial or engineered, is a “recombinant” nucleic acid
- Recombinant insulin may include any member derived from primates, humans, monkeys, rabbits, pigs, rodents, mice, rats, hamsters, gerbils, dogs, cats, and biologically active derivatives thereof, Mutant and variant forms of insulin with insulin are included as well as functional fragments and fusion proteins of insulin.
- the term "derivative" may be obtained by substituting a part of the structure of insulin with other atomic groups, substituents, etc., or may include one or more insulins bonded or fused with other biological substances, and of proteins known in the art. It includes a protein improved by an improvement method.
- one or more insulins combined with other biological substances are antibodies, antibody fragments, immunoglobulins, peptides, enzymes, growth factors, cytokines, transcription factors, toxins, antigenic peptides, hormones , transport proteins, motor function proteins, receptors, signaling proteins, storage proteins, membrane proteins, transmembrane proteins, internal proteins, external proteins, secretory proteins, viral proteins, glycoproteins,
- the cleaved protein, protein complex, or chemically modified protein may be a fused insulin fusion protein.
- Bio substances in the present invention include, without limitation, various small peptides, other proteins, and chemical means (eg, tags) useful for isolating or identifying bound polypeptides.
- the biological material may be fused to the N-terminus and/or C-terminus of the insulin amino acid sequence, and may be prepared by a method known in the art.
- some fusion domains capable of fusion with insulin are particularly useful for isolation of fusion proteins by affinity chromatography.
- suitable matrices for affinity chromatography are used, for example glutathione-, amylase- and nickel- or cobalt-conjugated resins.
- Many such matrices are available in "kit” form, such as the Pharmacia GST purification system and the QLAexpressTM system (Qiagen, Qiagen) useful with a (HIS6) fusion partner.
- the fusion domain can be selected to facilitate detection of insulin.
- detection domains include various fluorescent proteins (eg, GFP) as well as "epitope tags," which are generally short peptide sequences for which specific antibodies are available.
- epitope tags for which specific monoclonal antibodies are readily available include the FLAG, influenza virus hemagglutinin (HA) and c-myc tags.
- the fusion domain has a protease cleavage site that allows the appropriate protease to partially digest the fusion protein and thus liberate the recombinant protein therefrom, e.g., a protease cleavage site for factor Xa or thrombin. The free protein can then be isolated from the fusion domain by subsequent chromatographic separation.
- the domain may include, for example, polyarginine-tag (Arg-tag), Strep-tag (Strep-tag), S-tag (S-tag), calmodulin-binding peptide, cellulose-binding domain (cellulose-binding domain), SBP-tag (SBPtag), chitin-binding domain (chitin-binding domain), glutathione S-transferase-tag, maltose-binding protein (maltose-binding domain) protein), NusA, TrxA, DsbA, protein A, protein G, and may further include human albumin.
- Arg-tag polyarginine-tag
- Strep-tag Strep-tag
- S-tag S-tag
- calmodulin-binding peptide cellulose-binding domain
- SBP-tag SBP-tag
- chitin-binding domain chitin-binding domain
- glutathione S-transferase-tag maltose-binding protein (malto
- insulin may be fused with a domain that stabilizes insulin in vivo ("stabilizer" domain).
- stabilizing in the present invention is meant something that increases serum half-life, whether the increase is due to reduced destruction, reduced clearance by the kidneys or other pharmacokinetic effects.
- Fusions with the Fc portion of immunoglobulins are known to confer desirable pharmacokinetic properties on a wide range of proteins. Likewise, fusion to human serum albumin may confer desirable properties. Other types of fusion domains that may be selected include multimerizing (eg, dimerizing, tetramerizing) domains and functional domains (which, if desired, confer additional biological functions). Fusions can be constructed such that the heterologous peptide is fused at the amino terminus of insulin and/or at the carboxy terminus of insulin.
- the amino acid sequence of insulin may be a recombinant polypeptide comprising a fragment thereof, a natural polypeptide, or a synthetic polypeptide.
- the polypeptide is multimeric.
- the polypeptide is a dimer. It will be appreciated in the art that some amino acid sequences of the binding agents described herein may vary without significantly affecting the structure or function of the protein. Accordingly, the present invention further encompasses variants of insulin that exhibit substantial activity or comprise a region of a fragment thereof.
- amino acid sequence variations include deletions, insertions, inversions, repetitions, and/or other types of substitutions.
- Insulin in the present invention may be modified to contain additional chemical moieties that are not normally part of the polypeptide.
- the derivatizing moiety may improve or otherwise modulate the solubility, biological half-life and/or absorption of the polypeptide. Moieties may also reduce or eliminate undesirable side effects of polypeptides and variants.
- Insulin of the present invention may be present in further combination with a bioactive compound to enhance the therapeutic effect.
- biologically active compound refers to a compound that modifies a disease when applied to a mammal having the disease.
- a biologically active compound may contain antagonistic or agonistic properties, or it may be a proteinaceous bioactive compound or a non-proteinaceous bioactive compound.
- the pharmaceutical composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers for the prevention and/or treatment of Charcot-Marie-Tooth disease,
- the present invention is not limited thereto.
- Another embodiment of the present invention relates to a stem cell therapeutic agent for treating Charcot-Marie-Tooth disease, including mesenchymal stem cells.
- the mesenchymal stem cells may have insulin-secreting ability.
- the mesenchymal stem cells may include insulin.
- insulin may be secreted from mesenchymal stem cells, but is not limited thereto.
- the mesenchymal stem cells may be contained in the cell therapy product in an undifferentiated state.
- the mesenchymal stem cells may be derived from humans or mammals other than humans, for example, may be derived from a human fetus.
- mammals other than humans may be dogs, cats, monkeys, cattle, sheep, pigs, horses, rats, mice or guinea pigs, but is not limited thereto.
- the mesenchymal stem cells are tonsils, umbilical cord, backpack, placenta, umbilical cord, umbilical cord blood, skin, peripheral blood, bone marrow, adipose tissue, muscle, liver, nerve tissue, periosteum, fetal membrane, synovial membrane, synovial fluid, amniotic membrane, meniscus It may be derived from the superior cartilage, anterior cruciate ligament, articular chondrocytes, baby teeth, perivascular cells, trabecular bone, subpatellar fat mass, spleen and thymus, etc., and may be derived from, for example, human tonsils or human umbilical cord. .
- the term "cell therapy” refers to proliferating or selecting living autologous, allogenic, or xenogenic cells in vitro, or using various methods to restore the function of cells and tissues. It refers to drugs used for the purpose of treatment, diagnosis, and prevention through a series of actions that change characteristics (Article 2 of the Product Authorization Review Notice for Biological Products, etc. announced by the KFDA (2008-78)).
- the present invention relates to a pharmaceutical composition for preventing or treating Charcot-Marie-Tooth disease, comprising insulin secreted from mesenchymal stem cells or mesenchymal stem cells, wherein insulin secreted from mesenchymal stem cells or mesenchymal stem cells is Charcot-Marie-Tooth disease can be prevented or treated as a mechanism to restore myelination through the effect of promoting the proliferation ability of Schwann cells.
- FIG. 1 is a graph showing the results of stem cell ability analysis by separating mesenchymal stem cells from tonsils according to an embodiment of the present invention.
- 2A is a photograph confirming the ability to differentiate fat according to an embodiment of the present invention.
- Figure 2b is a graph of the result of confirming the fat differentiation ability according to an embodiment of the present invention.
- Figure 2c is a photograph confirming the osteoblast differentiation ability according to an embodiment of the present invention.
- Figure 2d is a graph of the result of confirming the osteoblast differentiation ability according to an embodiment of the present invention.
- Figure 2e is a photograph confirming the cartilage differentiation ability according to an embodiment of the present invention.
- Figure 3a is a photograph showing the results of screening for insulin by analyzing the secreted protein increased by co-culturing tonsil-derived mesenchymal stem cells with Schwann cells according to an embodiment of the present invention.
- Figure 3b is a graph comparing the insulin gene expression of mesenchymal stem cells by co-culturing tonsil-derived mesenchymal stem cells with Schwann cells according to an embodiment of the present invention.
- Figure 4a is a graph confirming that the proliferation capacity of Schwann cells increases when the Schwann cells are treated with insulin protein by concentration according to an embodiment of the present invention.
- Figure 4b is a graph confirming that the proliferation capacity of Schwann cells increases when the Schwann cells are treated with insulin protein by concentration according to an embodiment of the present invention.
- Figure 4c is a graph confirming that the proliferation capacity of Schwann cells increases when the Schwann cells are treated with insulin protein by concentration according to an embodiment of the present invention.
- Figure 4d is a photograph showing the result confirming that the proliferation ability of Schwann cells is activated through ERK and Akt pathways when 100 nM of insulin protein is treated in Schwann cells according to an embodiment of the present invention.
- FIG. 5 is a graph showing the result confirming that insulin expression in umbilical cord-derived mesenchymal stem cells is increased when co-cultured with umbilical cord-derived mesenchymal stem cells with Schwann cells according to an embodiment of the present invention.
- 6A is a graph confirming that Rotarod behavioral ability increases when insulin protein is administered to mice with Charcot-Marie-Tooth disease according to an embodiment of the present invention.
- 6B is a graph confirming that the GripStrength behavioral ability increases when insulin protein is administered to mice with Charcot-Marie-Tooth disease according to an embodiment of the present invention.
- FIG. 7 is a graph confirming that PMP22 gene expression is reduced when insulin protein is administered to mice with Charcot-Marie-Tooth disease according to an embodiment of the present invention.
- FIG. 8A is a photograph confirming that the myelination of the nervous tissue is increased when insulin protein is administered to mice with Charcot-Marie-Tooth disease according to an embodiment of the present invention.
- 8B is a graph confirming that the myelination of nervous tissue is increased when insulin protein is administered to mice with Charcot-Marie-Tooth disease according to an embodiment of the present invention.
- FIG. 8c is a graph confirming that the thickness of myelination of the nervous tissue increases according to the concentration of insulin protein in mice with Charcot-Marie-Tooth disease according to an embodiment of the present invention.
- FIG. 8d is a photograph confirming that myelination of nerve tissue is increased when insulin protein is administered to mice with Charcot-Marie-Tooth disease according to an embodiment of the present invention.
- FIG. 8e is a graph confirming that myelination of nerve tissue is increased when insulin protein is administered to mice with Charcot-Marie-Tooth disease according to an embodiment of the present invention.
- 8f is a photograph confirming that the myelination of the nervous tissue is increased when insulin protein is administered to mice with Charcot-Marie-Tooth disease according to an embodiment of the present invention.
- 8g is a graph confirming that the myelination of the nervous tissue is increased when insulin protein is administered to mice with Charcot-Marie-Tooth disease according to an embodiment of the present invention.
- 9A is a photograph confirming that calf muscle tissue formation is increased when insulin protein is administered to mice with Charcot-Marie-Tooth disease according to an embodiment of the present invention.
- 9B is a graph confirming that calf muscle tissue formation is increased when insulin protein is administered to mice with Charcot-Marie-Tooth disease according to an embodiment of the present invention.
- 9c is a photograph confirming that calf muscle tissue formation is increased when insulin protein is administered to mice with Charcot-Marie-tooth disease according to an embodiment of the present invention.
- 9D is a graph confirming that calf muscle tissue formation is increased when insulin protein is administered to mice with Charcot-Marie-Tooth disease according to an embodiment of the present invention.
- 9E is a graph confirming that calf muscle tissue formation is increased when insulin protein is administered to mice with Charcot-Marie-Tooth disease according to an embodiment of the present invention.
- a pharmaceutical composition for preventing or treating Charcot-Marie-Tooth disease comprising mesenchymal stem cells.
- the cells obtained by culturing tonsil-derived mesenchymal stem cells in ⁇ -MEM containing FBS at 37° C., saturated humidity and 5% CO 2 were obtained at 80% confluence.
- the obtained cells were analyzed for the expression pattern of mesenchymal stem cell-specific cell surface markers (CD90, CD105, CD73, CD166 and CD44) according to the requirements of ISCT (International Society for Cellular Therapy), and mesenchymal stem cells for purity analysis
- Cells expressing negative markers (CD34, CD45, CD19, CD11b, CD14 and HLA-DR) were analyzed by flow cytometry. The results are shown in FIG. 1 .
- tonsil-derived mesenchymal stem cells expressed more than 95% of mesenchymal stem cell-specific cell surface markers, and did not express negative markers of mesenchymal stem cells. Cells were confirmed.
- Example 2 Confirmation of the differentiation ability of tonsil-derived mesenchymal stem cells into adipocytes, osteoblasts or chondrocytes
- tonsil-derived mesenchymal stem cells After culturing tonsil-derived mesenchymal stem cells, they were each differentiated using a differentiation medium that differentiates them into typical mesenchymal cells, such as adipocytes, osteoblasts, or chondrocytes.
- a differentiation medium that differentiates them into typical mesenchymal cells, such as adipocytes, osteoblasts, or chondrocytes.
- the cells obtained by culturing tonsil-derived mesenchymal stem cells in ⁇ -MEM containing FBS at 37° C., saturated humidity and 5% CO 2 were obtained at 80% confluence. After culturing for 10 to 30 days in a differentiation medium for differentiating the obtained cells into osteoblasts, chondrocytes or adipocytes, it was confirmed whether the cells were differentiated or not.
- StemPro Adipogenesis Differentiation Kit was used for adipocyte differentiation
- StemPro Osteogenesis Differentiation Kit was used for osteoblast differentiation
- BMP-6, TGF ⁇ 3, ITS, dexamethasone, ascorbic acid, L-proline were used in DMEM medium for chondrocyte differentiation.
- a medium containing sodium pyruvate was used.
- Adipocytes were stained with oil-red O, osteoblasts were stained with Alizarin red S, and chondrocytes were stained with Safranin-O, and the results are shown in FIGS. 2a to 2d.
- RNA was reacted at 65° C. for 5 minutes, 23° C. for 10 minutes, 55° C. for 10 minutes, and 80° C. for 10 minutes using SuperScript IV Reverse Transcriptase Kit (Invitrogen).
- tonsil-derived mesenchymal stem cells were differentiated into mesenchymal cells, such as adipocytes, osteoblasts, or chondrocytes, under a suitable differentiation medium.
- Antibody arrays were performed to find secreted substances that promote the proliferation of Schwann cells during co-culture of Schwann cells and tonsil-derived mesenchymal stem cells. Specifically, for protein analysis, experiments were conducted using RayBio Biotin Label-based Human Antibody Array (#AAH-BLG-1-4, RayBiotech, Inc., GA, USA), and Axon GenePix 4000B scanner (Molecular Devices, CA) , USA) and analyzed using GenePix Pro 6.0 (Molecular Devices, CA, USA). The results are shown in Fig. 3a and Table 3, and insulin was screened with a substance likely to induce the proliferation of Schwann cells through a literature search, etc., and the results are shown in Figs. 3a and Table 3.
- Example 2 insulin expression was confirmed in mesenchymal stem cells co-cultured using an insulin primer in the same manner as for gene expression analysis through qRT-PCR, and the results are shown in FIG. 3B and Table 4.
- the degree of cell proliferation was measured using a CCK-8 (Dojindo) test method to measure the absorbance at 450 nM in a spectrophotometer.
- ATP was measured using CellTiter-Glo Luminescent Cell Viability Assay (Promega Corporation), and finally 5-bromo-2'-deoxyuridine (BrdU), which is bound during DNA synthesis of cells, was confirmed.
- This test method was analyzed using Cell Proliferation ELISA, BrdU (colorimetric) (Roche).
- the cells were obtained 24 hours later, the pellet was put in RIPA buffer, the cells were disrupted by a sonicator, and the supernatant was centrifuged at 13,000 rpm at 4°C for 15 minutes. After protein quantitation, 30 ug of protein was loaded on an SDS-PAGE gel. After that, the gel loaded in PVDF was transferred and blocked with 5% skim milk for 1 hour, and then P-ERK1/2, ERK1/2, P-AKT, AKT, and ⁇ -actin antibodies were applied at 4°C for 24 hours. pasted After the HRP-attached secondary antibody reaction and washing process, the band of the protein was confirmed using the ECL solution, and the results are shown in FIG. 4D .
- Example 2 insulin expression was measured in mesenchymal stem cells co-cultured with Schwann cells using an insulin primer in umbilical cord-derived mesenchymal stem cells in the same manner as gene expression analysis through qRT-PCR, and the results are shown in FIG. 5 and Table 8.
- Insulin 12 U/kg concentration was intravenously administered to 5-week-old Charcot-Marie-Tooth disease mice, and 2 weeks later, the results of confirming the increase in behavioral ability through the Rotarod experiment as in Example 5 are shown in FIGS. 6A and 9 .
- Insulin 12 U/kg concentration was intravenously administered to 5-week-old Charcot-Marie-tooth disease mice, and 2 weeks later, the results of confirming the increase in behavioral ability through the Grip Strength experiment as in Example 5 are shown in Figures 6b and 10. .
- Insulin 12 U/kg concentration was intravenously administered to 5-week-old Charcot-Marie-Tooth disease mice, and sciatic nerve tissue was collected 2 weeks later, and the same as in the gene expression analysis through qRT-PCR in Example 2
- the expression of PMP22 was confirmed in mouse nervous tissue with the PMP22 primer, and the results are shown in FIGS. 7 and 11 .
- Insulin 12 U/kg concentration was intravenously administered to 5-week-old Charcot-Marie-Tooth disease mice, and sciatic nerve tissue was collected 2 weeks later, and the same method as in Example 7 for tissue structure analysis with a transmission electron microscope. The observed results are shown in FIGS. 8A to 8C and Tables 12 and 13.
- a concentration of 12 U/kg of insulin was intravenously administered to a 5-week-old Charcot-Marie-Tooth disease mouse, and the sciatic nerve tissue was collected two weeks later, and the results observed with a confocal microscope in Example 7 It is shown in Figure 8d and Table 14.
- Insulin 12 U/kg concentration was intravenously administered to 5-week-old Charcot-Marie-Tooth disease mice, sciatic nerve tissue was collected one month later, and protein expression using western blotting in Example 3
- the MPZ expression level was confirmed using the MPZ antibody in the same manner as in the analysis, and the results are shown in FIGS. 8f, 8g and Table 15.
- Insulin 12 U/kg concentration was intravenously administered to 5-week-old Charcot-Marie-Tooth disease mice, and after 2 weeks, gastrocnemius muscle tissue was collected and the same method as for protein expression analysis using a fluorescent antibody in Example 7 By measuring the increase in muscle formation using the Dystrophin antibody, the results are shown in FIGS. 9a, 9b and Table 16.
- a concentration of 12 U/kg of insulin was intravenously administered to a 5-week-old Charcot-Marie-Tooth disease mouse, and 2 weeks later, the calf muscle tissue was photographed using an MRI device, and the results are shown in FIG. 9c .
- the cross-sectional area of the main muscle was measured and the volume of the muscle tissue was shown in FIGS. 9D and 17 and in FIGS. 9E and 18 .
- the present invention relates to a pharmaceutical composition for preventing or treating Charcot-Marie-Tooth disease, comprising mesenchymal stem cells or insulin secreted from mesenchymal stem cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
PPARG | |
Control | 1 |
Aipocyte | 64.5 |
RUNX2 | |
Control | 1 |
Osteocyte | 12.9 |
Antibody name | Genbank | Fold change |
TMEFF1 / Tomoregulin-1 | NM_003692 | 2.03 |
Insulin | NM_000207 | 1.82 |
IL-22 | NM_020525 | 1.26 |
PF4 | NM_002619 | 1.11 |
EDA-A2 | NM_001399 | 1.10 |
CXCR4 (fusin) | NM_003467 | 1.06 |
sFRP-4 | NM_003014 | 1.05 |
CCR7 | NM_001838 | 1.05 |
Human insulin | |
Tonsil-MSC | 1 |
Tonsil-MSC + S16 | 2.0 |
CCK-8 | 0 nM | 1 nM | 10 nM | 50 nM | 100 nM | 200 nM | 500 nM | 1000 nM |
1 | 1.03 | 1.09 | 1.16 | 1.18 | 1.19 | 1.21 | 1.21 |
ATP | 0 nM | 1 nM | 10 nM | 50 nM | 100 nM | 200 nM | 500 nM | 1000 nM |
1 | 1.08 | 1.13 | 1.20 | 1.23 | 1.18 | 1.22 | 1.06 |
BrdU | 0 nM | 1 nM | 10 nM | 50 nM | 100 nM | 200 nM | 500 nM | 1000 nM |
1 | 1.13 | 1.32 | 1.39 | 1.51 | 1.50 | 1.36 | 1.44 |
Human insulin | |
WK-MSC | 1 |
WJ-MSC + S16 | 2.34 |
Rotarod | WT | sham | insulin |
112.3 | 27.8 | 67.9 |
GripStrength | WT | sham | insulin |
8.9 | 6.2 | 7.7 |
PMP22 | WT | sham | insulin |
1 | 1305.36 | 986.69 |
Myelination | WT | sham | insulin |
100 | 13.59 | 82.99 |
Thickness | WT | sham | insulin |
3.32 | 0.67 | 2.53 |
MPZ | WT | sham | insulin |
1 | 0.20 | 0.69 |
MPZ | WT | sham | insulin |
100 | 3.84 | 44.12 |
Dystrophin | WT | sham | insulin |
1 | 0.27 | 0.94 |
CSA | WT | Sham | insulin | |||
Left | Right | Left | Right | Left | Right | |
0.328 | 0.331 | 0.302 | 0.290 | 0.343 | 0.323 |
Volume | WT | sham | insulin | |||
Left | Right | Left | Right | Left | Right | |
2.754 | 2.782 | 2.533 | 2.438 | 2.879 | 2.712 |
Claims (11)
- 중간엽 줄기세포를 포함하는 샤르코-마리-투스병 예방 또는 치료용 약학적 조성물.
- 제1항에 있어서, 상기 중간엽 줄기세포는 인슐린 분비능을 갖는 것인, 샤르코-마리-투스병 예방 또는 치료용 약학적 조성물.
- 제1항에 있어서, 상기 중간엽 줄기세포는 인슐린을 포함하는 것인, 샤르코-마리-투스병 예방 또는 치료용 약학적 조성물.
- 제1항에 있어서, 상기 중간엽 줄기세포는 인간 편도 또는 인간 탯줄 유래인 것인, 샤르코-마리-투스병 예방 또는 치료용 약학적 조성물.
- 인슐린 또는 이의 유도체를 유효성분으로 포함하는 샤르코-마리-투스병 예방 또는 치료용 약학적 조성물.
- 제5항에 있어서, 상기 인슐린은 중간엽 줄기세포에서 분비된 인슐린인 것인, 샤르코-마리-투스병 예방 또는 치료용 약학적 조성물.
- 제5항에 있어서, 상기 중간엽 줄기세포는 인간 편도 또는 인간 탯줄 유래인 것인, 샤르코-마리-투스병 예방 또는 치료용 약학적 조성물.
- 중간엽 줄기세포를 포함하는 샤르코-마리-투스병 치료용 줄기세포 치료제.
- 제8항에 있어서, 상기 중간엽 줄기세포는 인슐린 분비능을 갖는 것인, 샤르코-마리-투스병 치료용 줄기세포 치료제.
- 제8항에 있어서, 상기 중간엽 줄기세포는 인슐린을 포함하는 것인, 샤르코-마리-투스병 치료용 줄기세포 치료제.
- 제8항에 있어서, 상기 중간엽 줄기세포는 인간 편도 또는 인간 탯줄 유래인 것인, 샤르코-마리-투스병 치료용 줄기세포 치료제.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/912,913 US20230081894A1 (en) | 2020-03-20 | 2021-01-22 | Pharmaceutical composition, for preventing or treating charcot-marie-tooth disorder, comprising mesenchymal stem cells or insulin secreted by mesenchymal stem cells |
EP21772334.5A EP4122476A4 (en) | 2020-03-20 | 2021-01-22 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE WITH MESENCHYMAL STEM CELLS OR INSULIN SECRETED BY MESENCHYMAL STEM CELLS |
AU2021239708A AU2021239708A1 (en) | 2020-03-20 | 2021-01-22 | Pharmaceutical composition, for preventing or treating Charcot-Marie-Tooth disorder, comprising mesenchymal stem cells or insulin secreted by mesenchymal stem cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0034461 | 2020-03-20 | ||
KR1020200034461A KR20210117771A (ko) | 2020-03-20 | 2020-03-20 | 중간엽 줄기세포 또는 중간엽 줄기세포에서 분비된 인슐린을 포함하는 샤르코-마리-투스병 예방 또는 치료용 약학적 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021187745A1 true WO2021187745A1 (ko) | 2021-09-23 |
Family
ID=77771281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/000941 WO2021187745A1 (ko) | 2020-03-20 | 2021-01-22 | 중간엽 줄기세포 또는 중간엽 줄기세포에서 분비된 인슐린을 포함하는 샤르코-마리-투스병 예방 또는 치료용 약학적 조성물 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230081894A1 (ko) |
EP (1) | EP4122476A4 (ko) |
KR (2) | KR20210117771A (ko) |
AU (1) | AU2021239708A1 (ko) |
WO (1) | WO2021187745A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230110194A (ko) * | 2022-01-13 | 2023-07-21 | 주식회사 툴젠 | 슈반 세포 특이적 프로모터 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100298763B1 (ko) * | 1992-06-12 | 2001-10-24 | 세파론, 인코포레이티드 | 말초신경병의예방및치료 |
US20090214487A1 (en) * | 2006-01-12 | 2009-08-27 | Timothy Varney | Use of mesenchymal stem cells for treating genetic diseases and disorders |
KR20160022758A (ko) * | 2014-08-19 | 2016-03-02 | 이화여자대학교 산학협력단 | 편도 유래 중간엽 줄기세포로부터 인슐린 분비 세포의 분화 방법 |
KR20160085571A (ko) * | 2015-01-08 | 2016-07-18 | 이화여자대학교 산학협력단 | 편도 유래 중간엽 줄기세포로부터 근육 세포의 분화방법 |
KR20190112668A (ko) * | 2018-03-26 | 2019-10-07 | 이화여자대학교 산학협력단 | 편도 유래 중간엽 줄기세포로부터 운동신경세포의 분화방법 |
KR20200034461A (ko) | 2018-09-21 | 2020-03-31 | 주식회사 포스코 | 롤 측정장치 및 이를 이용한 롤 측정방법 |
-
2020
- 2020-03-20 KR KR1020200034461A patent/KR20210117771A/ko not_active IP Right Cessation
-
2021
- 2021-01-22 AU AU2021239708A patent/AU2021239708A1/en active Pending
- 2021-01-22 US US17/912,913 patent/US20230081894A1/en active Pending
- 2021-01-22 EP EP21772334.5A patent/EP4122476A4/en active Pending
- 2021-01-22 WO PCT/KR2021/000941 patent/WO2021187745A1/ko unknown
-
2022
- 2022-04-13 KR KR1020220045896A patent/KR20220062456A/ko not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100298763B1 (ko) * | 1992-06-12 | 2001-10-24 | 세파론, 인코포레이티드 | 말초신경병의예방및치료 |
US20090214487A1 (en) * | 2006-01-12 | 2009-08-27 | Timothy Varney | Use of mesenchymal stem cells for treating genetic diseases and disorders |
KR20160022758A (ko) * | 2014-08-19 | 2016-03-02 | 이화여자대학교 산학협력단 | 편도 유래 중간엽 줄기세포로부터 인슐린 분비 세포의 분화 방법 |
KR20160085571A (ko) * | 2015-01-08 | 2016-07-18 | 이화여자대학교 산학협력단 | 편도 유래 중간엽 줄기세포로부터 근육 세포의 분화방법 |
KR20190112668A (ko) * | 2018-03-26 | 2019-10-07 | 이화여자대학교 산학협력단 | 편도 유래 중간엽 줄기세포로부터 운동신경세포의 분화방법 |
KR20200034461A (ko) | 2018-09-21 | 2020-03-31 | 주식회사 포스코 | 롤 측정장치 및 이를 이용한 롤 측정방법 |
Non-Patent Citations (9)
Title |
---|
"Remington: The Science and Practice of Pharmacy", PHARMACEUTICAL PRESS |
ENCELLS CO., LTD: "Development of Next-Generation Medicines for Rare Muscular Disease using Enhanced Neo Cell", TECHNOLOGY-BASED STARTUPS AND INVESTMENTS LINKAGE, 1 August 2018 (2018-08-01) |
LEAL, A. ; ICHIM, T.E. ; MARLEAU, A.M. ; LARA, F. ; KAUSHAL, S. ; RIORDAN, N.H.: "Immune effects of mesenchymal stem cells: Implications for Charcot-Marie-Tooth disease", CELLULAR IMMUNOLOGY, ACADEMIC PRESS, SAN DIEGO, CA., US, vol. 253, no. 1-2, 1 January 2008 (2008-01-01), US, pages 11 - 15, XP025410601, ISSN: 0008-8749, DOI: 10.1016/j.cellimm.2008.06.003 * |
LINDVALL ET AL., ARCH. NEUROL., vol. 46, 1989, pages 615 - 31 |
PARK S., CHOI Y, JUNG N, KIM J, S JUNG: "Restoration of neuromuscular function in charcot-marie-tooth (CMT)1a disease by human tonsil-derived MSC (T-MSC)", CYTOTHERAPY, vol. 19, no. 5, 1 May 2017 (2017-05-01), XP055851749 * |
PARK SAEYOUNG, JUNG NAMHEE, MYUNG SEOHA, CHOI YOONYOUNG, CHUNG KI, CHOI BYUNG-OK, JUNG SUNG-CHUL: "Differentiation of Human Tonsil-Derived Mesenchymal Stem Cells into Schwann-Like Cells Improves Neuromuscular Function in a Mouse Model of Charcot-Marie-Tooth Disease Type 1A", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 19, no. 8, 14 August 2018 (2018-08-14), pages 2393, XP055851751, DOI: 10.3390/ijms19082393 * |
SAMSUNG SEOUL HOSPITAL, RESEARCH-DRIVEN HOSPITAL FOSTERING R&D, 1 January 2020 (2020-01-01) |
SAMSUNG SEOUL HOSPITAL: "Development of Customized Diagnosis and Treatment Methods for Charcot-Marie-Tooth Disease", 1 January 2014 |
See also references of EP4122476A4 |
Also Published As
Publication number | Publication date |
---|---|
US20230081894A1 (en) | 2023-03-16 |
EP4122476A4 (en) | 2023-05-10 |
KR20210117771A (ko) | 2021-09-29 |
AU2021239708A1 (en) | 2022-11-24 |
KR20220062456A (ko) | 2022-05-17 |
EP4122476A1 (en) | 2023-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016200219A1 (en) | Modified interleukin-7 protein and uses thereof | |
WO2014133324A1 (ko) | 신규한 인슐린 아날로그 및 이의 용도 | |
WO2011049414A2 (ko) | 지방조직 유래 성체 줄기세포 이동을 유도하는 방법 | |
WO2015156649A1 (ko) | 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 | |
WO2017142367A1 (ko) | 중간엽 줄기세포 또는 xcl1을 포함하는 근육질환의 예방 또는 치료용 약학적 조성물 | |
US6749847B2 (en) | Hybrid cytokine of IL-7 and β-chain of hepatocyte growth factor | |
KR20140099526A (ko) | 안구 건조증의 치료를 위한 jnk 신호 전달 경로의 세포-투과성 펩타이드 억제자의 용도 | |
WO2021096275A1 (ko) | 변형된 인터루킨-7 및 tgf 베타 수용체 ii를 포함하는 융합단백질 및 이의 용도 | |
WO2016006963A1 (en) | Insulin analogue | |
WO2021187745A1 (ko) | 중간엽 줄기세포 또는 중간엽 줄기세포에서 분비된 인슐린을 포함하는 샤르코-마리-투스병 예방 또는 치료용 약학적 조성물 | |
WO2010131917A2 (ko) | 줄기세포의 세포 활성과 연관된 tsp-1, tsp-2, il-17br 및 hb-egf 및 이들의 용도 | |
US7208469B2 (en) | Therapeutic method | |
KR20220118709A (ko) | 중간엽 줄기세포 증식 및/또는 이동 촉진용 조성물 | |
WO2016027990A1 (ko) | Dusp5를 유효성분으로 모두 포함하는 골대사성 질환의 예방 또는 치료용 약학적 조성물 | |
WO2012161519A1 (en) | An adult stem cell line introduced with hepatocyte growth factor gene and neurogenic transcription factor gene with basic helix-loop-helix motif and uses thereof | |
WO2016117960A1 (ko) | 면역질환 치료 효능을 갖는 grim19이 과발현된 중간엽줄기세포 및 이의 용도 | |
WO2018203613A1 (ko) | 톨-유사 수용체(tlr) 억제를 위한 펩타이드 및 이를 포함하는 약학적 조성물 | |
WO2015023165A1 (ko) | 염증조절복합체 및 stat3 신호분자 차단을 통한 면역조절능 최적화된 안정화 중간엽줄기세포 | |
WO2022158800A1 (ko) | 면역세포 관용성 조절인자 과발현 줄기세포 및 이의 용도 | |
WO2022015106A1 (ko) | 종양괴사인자-자극된 유전자 6을 발현하는 중간엽 줄기세포를 포함하는 골관절염의 예방 또는 치료용 조성물 | |
KR20230074070A (ko) | 중간엽 줄기세포 또는 중간엽 줄기세포에서 분비된 인슐린을 포함하는 샤르코-마리-투스병 예방 또는 치료용 약학적 조성물 | |
WO2021107635A1 (ko) | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 nk 세포를 포함하는 항암 치료용 조성물 | |
WO2018004294A9 (ko) | 인간 성장호르몬 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물 | |
WO2022270853A1 (ko) | Clcf1 단백질 및 이의 용도 | |
WO2016159695A1 (ko) | Ssu72를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21772334 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021772334 Country of ref document: EP Effective date: 20221020 |
|
ENP | Entry into the national phase |
Ref document number: 2021239708 Country of ref document: AU Date of ref document: 20210122 Kind code of ref document: A |